Recombinant Pan paniscus E3 ubiquitin-protein ligase RING1 (RING1)

What is Pan paniscus E3 ubiquitin-protein ligase RING1 and how does it function in the ubiquitination pathway?

Pan paniscus RING1 belongs to the Really Interesting New Gene (RING) family of E3 ubiquitin ligases that catalyze the transfer of ubiquitin from E2~Ub to substrate proteins. Unlike HECT-type E3 ligases that form catalytic intermediates with ubiquitin, RING1 acts as a scaffold that positions E2~Ub and substrate proteins for direct ubiquitin transfer . The protein contains a characteristic RING finger domain that coordinates two zinc ions through a cross-braced arrangement of cysteine and histidine residues, creating a platform for E2 binding . This structural arrangement is critical for its catalytic function.

In the ubiquitination cascade, RING1 works sequentially with E1 (ubiquitin-activating) and E2 (ubiquitin-conjugating) enzymes to facilitate the attachment of ubiquitin to lysine residues on target substrates . This post-translational modification can signal for protein degradation, alter protein function, or influence cellular localization, depending on the type and length of ubiquitin chains formed.

Which E2 ubiquitin-conjugating enzymes preferentially work with RING1 and how does this affect ubiquitination patterns?

RING1 demonstrates clear preferences for specific E2 enzymes, which significantly impacts its ubiquitination activity and chain specificity. Studies of RING-type E3 ligases have shown that they most efficiently work with members of the UbcH5 family (UbcH5a, UbcH5b, UbcH5c) and UbcH6 .

Experimental data indicates differential activities with these E2 enzymes:

The E2 selection affects both the processivity and substrate selectivity of RING1-mediated ubiquitination . UbcH5c typically generates more polyubiquitin chains than other E2s, while UbcH6 appears more selective in promoting monoubiquitination of substrates .

How should researchers design in vitro ubiquitination assays to accurately assess RING1 activity?

Designing robust in vitro ubiquitination assays for RING1 requires careful consideration of multiple factors:

Essential components:

• Purified E1 enzyme (typically mammalian UBA1)

• Appropriate E2 enzyme (preferably UbcH5a, UbcH5b, UbcH5c, or UbcH6)

• Recombinant RING1 protein (either full-length or RING domain sufficient)

• Ubiquitin (wild-type or tagged for detection)

• ATP regeneration system (ATP, creatine phosphate, creatine kinase)

• Appropriate buffer (typically containing DTT, zinc, and magnesium)

• Substrate protein (if studying specific substrate ubiquitination)

Recommended reaction setup:

• Pre-incubate E1 with ubiquitin and ATP for 5-10 minutes at 30°C

• Add E2 enzyme and incubate for additional 5 minutes

• Add RING1 and substrate to initiate the reaction

• Incubate at 30-37°C for 30-60 minutes

• Stop the reaction with SDS-PAGE loading buffer containing β-mercaptoethanol

• Analyze by immunoblotting with anti-ubiquitin antibodies

Critical controls:

• Negative controls: Reactions lacking ATP, E1, E2, or RING1 individually

• RING1 mutant lacking catalytic activity (mutations in zinc-coordinating residues)

• Positive control: Well-characterized E3-substrate pair

The addition of a binding partner like Bmi1 can significantly enhance RING1's E3 ligase activity in a dose-dependent manner, which should be considered when designing these assays .

What purification strategies yield functional recombinant Pan paniscus RING1 protein suitable for biochemical studies?

Obtaining properly folded, functional RING1 requires specific consideration for its zinc-coordinating domain:

Bacterial expression strategy:

• Clone RING1 cDNA into an expression vector with affinity tag (His6 or GST)

• Transform into E. coli BL21(DE3) or Rosetta strains

• Culture in media supplemented with 50-100 μM ZnCl₂

• Induce at low temperature (16-18°C) with reduced IPTG concentration (0.1-0.5 mM)

• Include zinc and reducing agents in all purification buffers

Purification protocol:

• Lyse cells in buffer containing 20 mM Tris-HCl pH 7.5, 150-300 mM NaCl, 10% glycerol, 1 mM DTT, 20 μM ZnCl₂, and protease inhibitors

• Perform affinity chromatography (Ni-NTA for His-tagged or glutathione-Sepharose for GST-tagged)

• Include imidazole wash steps (20-40 mM) to reduce non-specific binding

• Elute with higher imidazole (250-300 mM) or reduced glutathione

• Further purify by size exclusion chromatography

• Verify protein quality by SDS-PAGE and activity assays

Critical considerations:

• The N-terminal RING domain (amino acids 1-331) is sufficient for E3 ligase activity in vitro

• Inclusion of zinc in all buffers is essential for maintaining the structural integrity of the RING domain

• The protein should be stored with reducing agents (1-5 mM DTT) to prevent oxidation of critical cysteine residues

• Flash-freeze aliquots in liquid nitrogen and avoid multiple freeze-thaw cycles

How can researchers effectively study RING1-substrate interactions and validate potential targets?

Identifying and validating RING1 substrates requires a multi-faceted approach:

Substrate identification strategies:

• Candidate-based screening:

  • Select potential substrates based on homology with known targets of human RING1

  • Focus on proteins involved in chromatin regulation, particularly histones

  • Test ubiquitination of these candidates in vitro

• Unbiased screening approaches:

  • Affinity purification coupled with mass spectrometry (AP-MS)

  • Proximity-based labeling (BioID, APEX)

  • Ubiquitin remnant profiling to identify differentially ubiquitinated proteins

Validation workflow:

• In vitro validation:

  • Perform ubiquitination assays with purified recombinant substrate

  • Identify ubiquitination sites by mass spectrometry

  • Generate lysine-to-arginine mutants to confirm specific sites

• Cellular validation:

  • Express wild-type or catalytically inactive RING1 in cells

  • Immunoprecipitate substrate and blot for ubiquitin

  • Perform cycloheximide chase experiments to assess substrate stability

  • Use proteasome inhibitors to determine if ubiquitination leads to degradation

Histone H2A is a well-established substrate for RING1, with monoubiquitination occurring at lysine 119 . This provides a positive control for substrate validation experiments and a benchmark for detecting novel substrates.

How do mutations in conserved RING domain residues affect the catalytic mechanism of RING1?

Mutations in the RING domain have profound effects on RING1 function, with specific outcomes depending on the residue affected:

Critical zinc-coordinating residues:
Mutations of the conserved cysteine and histidine residues that coordinate zinc ions completely abolish E3 ligase activity. For example, mutation of conserved cysteines C228/C231 to alanine eliminates catalytic activity . These residues maintain the structural integrity of the RING domain and are essential for E2 binding.

Allosteric regulatory sites:
Certain residues outside the direct E2-binding interface can affect RING1 activity through allosteric mechanisms. These mutations may alter the dynamics of the RING domain or its ability to position the E2~Ub for catalysis.

Researchers have observed that mutations affecting RING1 auto-ubiquitination (such as at Lys 112) may have modulatory effects on RING1 function within larger complexes, potentially by influencing complex formation or stability .

What is the molecular basis for the enhanced E3 ligase activity observed when RING1 forms complexes with partner proteins?

The E3 ligase activity of RING1 is significantly enhanced when it forms complexes with partner proteins, particularly Bmi1 (B-cell-specific Moloney murine leukemia virus integration site 1):

Biochemical evidence:
In vitro studies demonstrate that addition of Bmi1 increases RING1's E3 ligase activity toward histone H2A in a dose-dependent manner . This enhancement is specific, as Bmi1 alone shows no detectable E3 ligase activity .

Structural basis:
The formation of a Ring-Ring heterodimer between RING1 and Bmi1 creates an optimal configuration for:

• Stabilizing RING1's active conformation

• Enhancing E2 binding and positioning

• Creating additional substrate interaction surfaces

• Potentially altering the dynamics of ubiquitin transfer

Functional implications:
This cooperative enhancement mechanism provides cellular regulation of RING1 activity through:

• Control of complex assembly

• Dose-dependent sensitivity to Bmi1 levels

• Tissue-specific expression of complex components

• Post-translational modifications affecting complex formation

This heterodimeric interaction exemplifies how RING-type E3 ligases can achieve functional diversity and regulatory control through complex formation with partner proteins.

How do post-translational modifications regulate RING1 activity in different cellular contexts?

RING1 activity is dynamically regulated by various post-translational modifications (PTMs):

Auto-ubiquitination:
RING1 undergoes self-ubiquitination in the presence of E1, E2 (particularly UbcH5c), and ubiquitin . While UbcH5c promotes polyubiquitination of RING1, other E2s like UbcH5a and UbcH5b primarily promote monoubiquitination . The specific sites and consequences of auto-ubiquitination may include:

• Potential regulation of protein stability

• Modulation of complex formation

• Allosteric effects on catalytic activity

• Creation of binding interfaces for ubiquitin-binding proteins

Phosphorylation:
Based on studies of RING E3 ligases, phosphorylation likely regulates RING1 through:

• Direct modulation of catalytic activity

• Altered substrate recognition

• Changes in subcellular localization

• Regulation of protein-protein interactions

Other potential modifications:

• SUMOylation

• Acetylation

• Methylation

Each modification creates a potential regulatory node that can be responsive to different cellular signals, allowing for context-specific modulation of RING1 function in various biological processes and pathways.

How do researchers address challenges in distinguishing direct RING1 substrates from indirect effects in cellular systems?

Distinguishing direct RING1 substrates from proteins affected indirectly presents significant challenges requiring multiple complementary approaches:

Technical strategies:

• Substrate trapping:

  • Use catalytically inactive RING1 mutants that can bind but not ubiquitinate substrates

  • Employ ubiquitin remnant profiling with RING1 knockdown/knockout

  • Use proximity labeling approaches (BioID, APEX) to identify proteins in close proximity to RING1

• In vitro confirmation:

  • Purify candidate substrates and perform in vitro ubiquitination assays

  • Determine ubiquitination sites by mass spectrometry

  • Test whether modification occurs in the absence of other proteins

• Temporal dynamics:

  • Use rapid induction or inhibition systems to distinguish primary from secondary effects

  • Perform time-course experiments following RING1 activation/inactivation

  • Monitor both ubiquitination and downstream consequences (e.g., degradation)

By integrating these approaches, researchers can build stronger evidence for direct RING1-substrate relationships while minimizing false positives arising from indirect effects within complex cellular networks.

What is the role of RING1 in transcriptional regulation and how does this contribute to cellular phenotypes?

RING1 plays crucial roles in transcriptional regulation through several mechanisms:

Histone modification:
As part of the Polycomb Repressive Complex 1 (PRC1), RING1 catalyzes the monoubiquitination of histone H2A at lysine 119 . This modification is associated with transcriptional repression and chromatin compaction. The E3 ligase activity of RING1 is enhanced by its binding partner Bmi1, which does not show E3 activity alone but significantly increases RING1's catalytic function .

Target genes:
RING1 primarily regulates:

• Developmental genes

• Cell cycle regulators

• Lineage-specific genes

• Stress response genes

Molecular mechanisms:

• Chromatin compaction through H2A ubiquitination

• Recruitment of additional repressive complexes

• Interference with transcription elongation

• Modulation of enhancer-promoter interactions

Cellular consequences:
RING1-mediated transcriptional regulation affects:

• Cell identity maintenance

• Differentiation potential

• Proliferation and cell cycle progression

• Response to cellular stress

• DNA damage response

These transcriptional effects form the molecular basis for RING1's roles in development, stem cell function, and potentially in disease processes when dysregulated.

What are the most common pitfalls in RING1 activity assays and how can researchers address them?

Researchers frequently encounter several challenges when working with RING1:

Problem 1: Low activity or inconsistent results

• Causes: Improper protein folding, oxidized cysteines, zinc deficiency, inactive E2

• Solutions:

  • Include 20-50 μM ZnCl₂ in all buffers

  • Use fresh DTT (1-5 mM) in reaction buffers

  • Verify E2 activity with a control E3 ligase

  • Express and purify protein at lower temperatures

  • Consider adding Bmi1 to enhance activity

Problem 2: High background or non-specific ubiquitination

• Causes: E2 auto-activity, contaminating E3 ligases, non-specific antibody binding

• Solutions:

  • Include negative controls lacking individual components

  • Use highly purified proteins (multi-step purification)

  • Pre-clear antibodies if using immunoblotting

  • Optimize E2 concentration (titration experiments)

Problem 3: Substrate modification not detected

• Causes: Wrong E2 selection, incorrect buffer conditions, inactive substrate

• Solutions:

  • Test multiple E2 enzymes (particularly UbcH5a/b/c and UbcH6)

  • Verify substrate quality by alternative means

  • Try different detection methods (mass spectrometry for low abundance modifications)

  • Include known substrate (e.g., histone H2A) as positive control

Problem 4: Poor reproducibility between experiments

• Causes: Protein instability, variable activity of components, technical variation

• Solutions:

  • Aliquot all components to avoid freeze-thaw cycles

  • Standardize protein concentrations carefully

  • Include internal standards for normalization

  • Document all experimental conditions meticulously

How can researchers optimize E2-E3 pairing for specific RING1-mediated ubiquitination reactions?

Optimizing E2-E3 pairing is critical for successful RING1 activity studies:

Systematic E2 profiling:
Testing RING1 with different E2 enzymes reveals distinct activity profiles. Research shows that RING1 works efficiently with:

• UbcH5a, UbcH5b, UbcH5c - promoting different degrees of chain formation

• UbcH6 - promoting predominantly monoubiquitination

• Limited or no activity with UbcH3, Rad6, E2-25K, UbcH7, and UbcH10

Considerations for specific applications:

Optimization strategy:

• Perform initial E2 screening with a panel of E2s

• Titrate E2 concentration for optimal signal-to-noise ratio

• Adjust reaction conditions (salt, pH, temperature) for each E2-E3 pair

• Consider adding cofactors like Bmi1 that enhance activity

• Validate findings with multiple detection methods

What strategies can overcome challenges in expressing and purifying full-length RING1 versus truncated domains?

Researchers face different challenges when working with full-length versus truncated RING1:

Full-length RING1 challenges:

• Lower expression levels in bacterial systems

• Increased tendency for inclusion body formation

• Higher susceptibility to proteolytic degradation

• More complex folding requirements

Domain-based approaches:
The N-terminal RING domain (amino acids 1-331) is sufficient for E3 ligase activity in vitro . This truncated version offers several advantages:

• Higher solubility in bacterial expression systems

• Simplified purification workflow

• Retained catalytic activity

• Reduced proteolytic degradation

Optimization strategies for full-length protein:

Practical recommendation:
For most biochemical studies of RING1's E3 ligase activity, the RING domain (1-331) provides an excellent compromise between ease of handling and functional relevance . For studies involving complex formation or interactions with regions outside the RING domain, full-length protein may be necessary despite the technical challenges.